» Articles » PMID: 17261409

Safety and Efficacy of Statins in Asians

Overview
Journal Am J Cardiol
Date 2007 Jan 31
PMID 17261409
Citations 98
Authors
Affiliations
Soon will be listed here.
Abstract

Asian patients frequently have heightened responses to therapeutic drugs. As a consequence, the recommended drug doses are often lower in Asian countries than in Western countries. This practice extends to the use of cardiovascular drugs, including statins for the treatment of dyslipidemia. Pharmacokinetic investigations have noted higher plasma levels of statins in Asians compared with Caucasians, although postmarketing data for all statins have not identified any particular safety issues, even when statins are given at equivalent doses. The potential mechanisms of heightened response to statins in Asians are related to genetically based differences in the metabolism of statins at the level of hepatic enzymes and drug transporters. Studies indicate that lower statin doses achieve lipid improvements in Asian patients comparable with those observed with higher doses in Caucasians. In conclusion, prescribing lower starting doses of statins in Asians appears warranted while research on this subject continues.

Citing Articles

Impact of an Intensive Lipid-Lowering Therapy Protocol on Achieving Target Low-Density Lipoprotein Cholesterol Levels in Patients With Acute Coronary Syndrome.

Seiyama K, Oka A, Miyoshi T, Sudo Y, Takagi W, Ugawa S Circ Rep. 2025; 7(2):131-138.

PMID: 39931715 PMC: 11807690. DOI: 10.1253/circrep.CR-24-0071.


Statins and the incidence of post-stroke depression: a systematic review and meta-analysis.

Cui C, Li J, Chen W Front Neurol. 2025; 15():1486367.

PMID: 39839884 PMC: 11746108. DOI: 10.3389/fneur.2024.1486367.


Machine learning-based prediction model for the efficacy and safety of statins.

Xiong Y, Liu X, Wang Q, Zhao L, Kong X, Da C Front Pharmacol. 2024; 15:1334929.

PMID: 39135800 PMC: 11317424. DOI: 10.3389/fphar.2024.1334929.


Analysis of Physician Compliance with Guideline-Directed Medical Therapy for Patients with Heart Failure with Reduced Ejection Fraction: A Real-World Study.

Wang G, Liu L, Wang X, Yu T, Xu H, Zhang T Rev Cardiovasc Med. 2024; 24(9):257.

PMID: 39076379 PMC: 11270074. DOI: 10.31083/j.rcm2409257.


Genetic heterogeneity in cardiovascular disease across ancestries: Insights for mechanisms and therapeutic intervention.

Soremekun O, Dib M, Rajasundaram S, Fatumo S, Gill D Camb Prism Precis Med. 2024; 1:e8.

PMID: 38550935 PMC: 10953756. DOI: 10.1017/pcm.2022.13.


References
1.
Saito M, Hirata-Koizumi M, Urano T, Miyake S, Hasegawa R . A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan. J Clin Pharm Ther. 2005; 30(1):21-37. DOI: 10.1111/j.1365-2710.2004.00605.x. View

2.
Wang K, Ting C . A randomized, double-blind, placebo-controlled, 8-week study to evaluate the efficacy and safety of once daily atorvastatin (10 mg) in patients with elevated LDL-cholesterol. Jpn Heart J. 2002; 42(6):725-38. DOI: 10.1536/jhj.42.725. View

3.
Matsuzawa Y, Kita T, Mabuchi H, Matsuzaki M, Nakaya N, Oikawa S . Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients. Circ J. 2003; 67(4):287-94. DOI: 10.1253/circj.67.287. View

4.
Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang W . A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999; 274(52):37161-8. DOI: 10.1074/jbc.274.52.37161. View

5.
Johnson J . Influence of race or ethnicity on pharmacokinetics of drugs. J Pharm Sci. 1998; 86(12):1328-33. DOI: 10.1021/js9702168. View